Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 744 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral dexamethasone Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

NCT00507442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

NCT01874561
View directory record Official record
Conditions
Cardiac Conduction and Repolarization
Interventions
Custirsen, Placebo, Moxifloxacin
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 24, 2026, 4:19 PM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

NCT07832110
View directory record Official record
Conditions
Post Operative Pain, Acute, Periodontitis
Interventions
Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00002678
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, melphalan, prednisone
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

NCT00475085
View directory record Official record
Conditions
Nausea
Interventions
aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo
Drug
Lead sponsor
Joseph Roscoe
Other
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 24, 2026, 4:19 PM EDT
Suspended Phase 1Phase 2 Interventional

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
View directory record Official record
Conditions
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions
Azeliragon, Stereotactic radiosurgery, Corticosteroid
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Recruiting Phase 4 Interventional

Post-op Prednisone and Glucose Monitoring in TKA

NCT07630896
View directory record Official record
Conditions
Osteoarthritis, Unicompartmental Knee Arthroplasty, Total Hip Arthroplasty (THA)
Interventions
Prednisone, Continuous Glucose Monitor, InkWell Health Tattoos
Drug · Device · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Withdrawn Phase 2 Interventional

High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

NCT03255473
View directory record Official record
Conditions
Sudden Sensorineural Hearing Loss (SSNHL)
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

NCT00558896
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, pomalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD

NCT01090180
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Dexamethasone, Placebo (sugar pill)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 24, 2026, 4:19 PM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

NCT03657420
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABI-009, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 24, 2026, 4:19 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
93
States / cities
Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 24, 2026, 4:19 PM EDT
Not listed Not applicable Interventional

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

NCT00835965
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Dexamethasone, Aprepitant, Placebo Dexamethasone
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 24, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT06351644
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
ON 123300, Dexamethasone
Drug
Lead sponsor
Adriana Rossi
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 24, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

NCT04407442
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Azacitidine, Daratumumab, Dexamethasone
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 24, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

NCT06863259
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 39 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

NCT01072773
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
bortezomib, cyclophosphamide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 24, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

NCT01583283
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 24, 2026, 4:19 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

The Bronchiolitis in Hospitalized Infants Study

NCT05994183
View directory record Official record
Conditions
Bronchiolitis
Interventions
Dexamethasone Oral
Drug
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
0 Months to 24 Months
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 24, 2026, 4:19 PM EDT